KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Total Liabilities (2016 - 2026)

Idexx Laboratories has reported Total Liabilities over the past 17 years, most recently at $1.7 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 2.78% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 2.78%, while the annual FY2025 figure was $1.7 billion, 2.78% up from the prior year.
  • Total Liabilities for Q4 2025 was $1.7 billion at Idexx Laboratories, down from $1.8 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $2.2 billion in Q3 2022 and troughed at $1.6 billion in Q1 2021.
  • A 5-year average of $1.8 billion and a median of $1.8 billion in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 32.74% in 2022 and later fell 17.36% in 2023.
  • Year by year, Total Liabilities stood at $1.7 billion in 2021, then grew by 22.37% to $2.1 billion in 2022, then decreased by 16.96% to $1.8 billion in 2023, then dropped by 4.35% to $1.7 billion in 2024, then grew by 2.78% to $1.7 billion in 2025.
  • Business Quant data shows Total Liabilities for IDXX at $1.7 billion in Q4 2025, $1.8 billion in Q3 2025, and $1.9 billion in Q2 2025.